Evidence map›Paper›PMID 36307879›Full record

ArticleEuropean journal of medical research2022

LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.

Lan Li, Xiao Wang, Yanni Ding, Nini Hui, Bingjie Su, Min Yang

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lan LiDepartment of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, Shaanxi, China.
Xiao WangDepartment of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, Shaanxi, China.
Yanni DingDepartment of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, Shaanxi, China.
Nini HuiDepartment of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, Shaanxi, China.
Bingjie SuDepartment of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, Shaanxi, China.
Min YangDepartment of Breast Surgery, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, Shaanxi, China. 355288191@qq.com.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLysophosphatidylcholine acyltransferase 1 (LPCAT1) is overexpressed in multiple human tumors. However, the role of LPCAT1 in hepatocellular carcinoma (HCC) has not been understood. We aim to explore the relationships between LPCAT1 expression and prognosis, clinicopathological features, tumor microenvironment (TME), immune cell infiltration, immune checkpoint gene expression, and related signaling pathways in HCC. Furthermore, we also explored the relationship between LPCAT1 expression and drug sensitivity to HCC treatment.

methodsThe expression profiles were acquired from the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (THPA). Immune status and infiltration in cancer tissues were explored using the single sample gene set enrichment analysis (ssGSEA) and CIBERSORT algorithm.

resultsLPCAT1 was overexpressed in HCC, and its expression was related to poor prognosis, LPCAT1 was an independent prognostic biomarker in HCC. Expression of LPCAT1 increased statistically with the increase of clinical stage and grade of HCC patients. GO and KEGG network analysis revealed that LPCAT1 positively associated molecules were mostly enriched in functions related to cell adhesion. The TME score of high-LPCAT1 group was significantly higher than that of low-LPCAT1 group. Immune infiltrating cells positively correlated with LPCAT1 expression were Macrophages M0, B cells memory, Dendritic cells activated, T cells regulatory and T cells gamma delta in HCC. We found a positive correlation between LPCAT1 and most immune checkpoint gene expression. The IC50 of 5-Fluorouracil, Gemcitabine, Mitomycin C, Sorafenib and Cabozantinib in patients with high-LPCAT1 expression was lower than that in patients with low-LPCAT1 expression. Our findings provide a wealth of information for further understanding of the biological functions and signaling pathways of LPCAT1 in HCC.

conclusionsLPCAT1 is an independent prognostic biomarker and associated with tumor microenvironment, immune cell infiltration, immune checkpoint expression and drug sensitivity in hepatocellular carcinoma.

Indexed as

Carcinoma, HepatocellularLiver Neoplasms1-Acylglycerophosphocholine O-AcyltransferaseBiomarkersHumansPrognosisSorafenibTumor Microenvironment1-Acylglycerophosphocholine O-AcyltransferaseBiomarkersLpcat1 protein, humanSorafenibDrug sensitivityHepatocellular carcinomaImmune cell infiltrationImmune checkpointLPCAT1PrognosisSignaling pathwayTumor microenvironment

Identifiers

PMID36307879
PMCPMC9617428
OpenAlexW4307508549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.